RICHMOND, Va.--(BUSINESS WIRE)--Market Update. Commonwealth Biotechnologies, Inc. (NASDAQ:CBTE) is pleased to provide an update on a number of recent successful initiatives. CBTE’s acquisitions of UK-based medicinal chemistry company Tripos Discovery Research Ltd (TDR) and Australian-based peptide chemistry company Mimotopes Pty Ltd in 2007 have transformed the Company into a full-service pre-clinical drug discovery services provider that is well positioned to capitalize on the rapid growth in global R&D outsourcing. The ‘one stop shop’ model adopted by the Group is already attracting new customers and winning a broader range of business from existing customers. The Company intends to continue its aggressive growth strategy through strengthening its existing brands and through continued strategic M&A activity.
